ClinicalTrials.gg

Program

claseprubart

Its studies are mostly in Myasthenia Gravis · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Dianthus Therapeutics.

Furthest: phase 3, since Feb 18, 20254 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dianthus Therapeutics44 open or runningphase 3since Feb 18, 2025Dec 15, 2023Dec 2026phase 2 · NCT06537999

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2023First study: phase 2 study in Myasthenia GravisFirst studyNCT06282159 · 65 enrolled · United States, Argentina, Canada and more
  2. Jul 31, 2024Phase 2 study in Multifocal Motor NeuropathyNCT06537999 · 46 enrolled · United States, Canada, China and more
  3. Feb 18, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06858579 · 256 planned · United States, Argentina, Australia and more
  4. May 27, 2026Phase 3 study in Myasthenia GravisNCT07647510 · 195 planned · United States, Georgia, Ukraine

Ahead

  1. Dec 2026Primary completion: phase 2 study in Multifocal Motor NeuropathyNCT06537999
  2. Dec 2028Primary completion: phase 3 study in Myasthenia GravisNCT07647510
  3. Dec 31, 2028Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06858579

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07647510Myasthenia Gravis · United States, Georgia, Ukraine3RecruitingDec 2028195
NCT06858579Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Australia and more3RecruitingDec 31, 2028256
NCT06537999Multifocal Motor Neuropathy · United States, Canada, China and more2Active, not recruitingDec 202646
NCT06282159Myasthenia Gravis · United States, Argentina, Canada and more2Active, not recruitingJul 28, 202565

How it is read

Names in the registry

  • “Claseprubart”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
claseprubart (Dianthus Therapeutics): development program | ClinicalTrials.gg